Evidence map›Paper›PMID 41093553›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Central Retinal Artery Occlusion Induced by Dupilumab: A Unique Manifestation of Eosinophilic Granulomatosis with Polyangiitis.

Takeshi Matsumoto, Chieko Shima, Hiroki Suga, Yuichi Kajiwara, Tomoya Matoba, Akiko Kaneko, Takahiro Fujiki, Yusuke Kusakabe, Emi Nakayama, Naoki Yamamoto and 1 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takeshi MatsumotoDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Chieko ShimaDepartment of Ophthalmology, Saiseikai-Noe Hospital, Japan.
Hiroki SugaDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Yuichi KajiwaraDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Tomoya MatobaDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Akiko KanekoDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Takahiro FujikiDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Yusuke KusakabeDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Emi NakayamaDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Naoki YamamotoDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.
Kensaku AiharaDepartment of Respiratory Medicine, Saiseikai-Noe Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab is widely used to treat type 2 inflammatory diseases; however, rare adverse events, including eosinophilic granulomatosis with polyangiitis (EGPA), may occur. We report the first case of central retinal artery occlusion (CRAO) as a manifestation of EGPA following dupilumab initiation after switching from mepolizumab in a 64-year-old man with severe asthma. The potential for rare but tragic complications such as CRAO should not be overlooked when using dupilumab, particularly when withdrawing or switching medications that suppress eosinophilic activity. Despite a generally poor visual prognosis, early recognition and multidisciplinary management are essential.

Indexed as

Antibodies, Monoclonal, HumanizedChurg-Strauss SyndromeGranulomatosis with PolyangiitisRetinal Artery OcclusionAsthmaHumansMaleMiddle AgedAntibodies, Monoclonal, Humanizeddupilumabmepolizumabasthmacentral retinal artery occlusiondupilumabeosinophilic granulomatosis with polyangiitis

Identifiers

PMID41093553
PMCPMC13265105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.